Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could one pill a day make HIV treatment easier? a new study asks patients

NCT ID NCT01322932

Disease control Sponsor: Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This study surveys HIV-positive adults who switch from taking two or three pills to a single pill containing the same three medicines (tenofovir, emtricitabine, and efavirenz). Researchers want to know if the simpler regimen improves how well patients take their medication, how they feel about side effects, and their overall satisfaction. The study follows 95 participants in Switzerland and uses questionnaires and medical records to track outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a single-pill combination of tenofovir, emtricitabine, and efavirenz
What this could lead to
If successful, this could show that a single-pill regimen improves adherence and satisfaction for people with HIV, making daily treatment simpler.
What could go wrong
This is a small survey study, so results may not apply to all HIV patients. It does not test a new drug, only a different way of taking existing ones.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

95 people

The number who actually took part.

Start date

Jul 2010

Finished

Feb 2012

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients under TDF-FTC-EFV followed up at the Service of Infectious Disease of the University Hospital of Lausanne and enrolled in the Swiss HIV Cohort Study (SHCS) Adherence subgroup: patients enrolled in the HIV adherence program at the pharmacy of the Department of Ambulatory Care \& Community Medicine in Lausanne.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * patients under TDF-FTC-EFV * followed up at the Service of Infectious Disease of the University Hospital of Lausanne * enrolled in the SHCS Exclusion Criteria: * patients receiving TDF-FTC-EFV in combination with other ARTs * patients under TDF-FTC-EFV for less than 3 months * patients not fluent in French

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV infection are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease Medication Adherence Patient Satisfaction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV infection

Contacts and locations

Locations

  • Centre Hospitalier Universitaire Vaudois et Policlinique Medicale Universitaire

    Lausanne, Canton of Vaud, 1011, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.